Nat Commun: Placebo controlled trial: Fecal microbiome transplantation to treat HIV

HIV is a chronic inflammatory disease in which patients exhibit chronic immune dysfunction, which may be affected by the microbiome, leading to persistent inflammation and leading to an excess risk of death.
years, efforts have been made to reduce the long-term consequences of chronic inflammation through different interventions to reduce a wide variety of HIV-related intestinal lymphatic tissue defects.
recently, researchers conducted a pilot double-blind study of 30 HIV-infected subjects who received antiretroviral therapy (ART) and had a CD4/CD8 ratio of .lt;1.
patients were randomly treated with weekly fecal microbiome capsules or placebos for 8 weeks.
donors make reasonable choices based on their microbiome markers.
researchers report that fecal microbiome transplantation (FMT) is safe, has nothing to do with serious adverse events, and can reduce HIV-related microbiome disorders.
FMT can cause changes in the structure of the gut microbiome, including a significant increase in α diversity, as well as mild and transient transplantation of the supply microbiome during treatment.
more significant transplants appear to have been achieved through the recent use of antibiotics before FMT.
the Lachnospiraceae and Ruminococcaceae families, which are usually consumed in HIV patients, are the best families to be planted across time points.
exploratory analysis, the researchers described a significant improvement in the FMT group in the intestinal fatty acid binding protein (IFABP), a biomarker of intestinal injury that independently predicts mortality.
, it is feasible and worth further study to operate the gut microbiome using non-invasive and safe FMT dosing strategies.
the test number NCT03008941.